448 related articles for article (PubMed ID: 29601212)
21. Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Dillon R; Hills R; Freeman S; Potter N; Jovanovic J; Ivey A; Kanda AS; Runglall M; Foot N; Valganon M; Khwaja A; Cavenagh J; Smith M; Ommen HB; Overgaard UM; Dennis M; Knapper S; Kaur H; Taussig D; Mehta P; Raj K; Novitzky-Basso I; Nikolousis E; Danby R; Krishnamurthy P; Hill K; Finnegan D; Alimam S; Hurst E; Johnson P; Khan A; Salim R; Craddock C; Spearing R; Gilkes A; Gale R; Burnett A; Russell NH; Grimwade D
Blood; 2020 Feb; 135(9):680-688. PubMed ID: 31932839
[TBL] [Abstract][Full Text] [Related]
22. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
[TBL] [Abstract][Full Text] [Related]
24. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
Vasseur L; Fenwarth L; Lambert J; de Botton S; Figeac M; Villenet C; Heiblig M; Dumas PY; Récher C; Berthon C; Lemasle E; Lebon D; Lambert J; Terré C; Celli-Lebras K; Dombret H; Preudhomme C; Cheok M; Itzykson R; Duployez N
Blood Adv; 2023 Aug; 7(15):4024-4034. PubMed ID: 37205853
[TBL] [Abstract][Full Text] [Related]
25. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
[TBL] [Abstract][Full Text] [Related]
26. Gemtuzumab Ozogamicin in
Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
[TBL] [Abstract][Full Text] [Related]
27. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
28. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
29. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
30. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Oñate G; Bataller A; Garrido A; Hoyos M; Arnan M; Vives S; Coll R; Tormo M; Sampol A; Escoda L; Salamero O; Garcia A; Bargay J; Aljarilla A; Nomdedeu JF; Esteve J; Sierra J; Pratcorona M
Blood Adv; 2022 Feb; 6(3):882-890. PubMed ID: 34516636
[TBL] [Abstract][Full Text] [Related]
31. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
[TBL] [Abstract][Full Text] [Related]
32. Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.
Wang B; Hua X; Zhang J; Gu W; Li H
Cancer Med; 2023 Apr; 12(8):9420-9433. PubMed ID: 36808479
[TBL] [Abstract][Full Text] [Related]
33. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; Vidriales MB; Sempere A; Tarín F; Colado E; Benavente C; Cedena MT; Sánchez J; Caballero-Velazquez T; Cordón L; Garces JJ; Simoes C; Martínez-Cuadrón D; Bernal T; Botella C; Grille S; Serrano J; Rodríguez-Medina C; Algarra L; Alonso-Domínguez JM; Amigo ML; Barrios M; García-Boyero R; Colorado M; Pérez-Oteyza J; Pérez-Encinas M; Costilla-Barriga L; Sayas MJ; Pérez O; González-Díaz M; Pérez-Simón JA; Martínez-López J; Sossa C; Orfao A; San Miguel JF; Sanz MÁ; Montesinos P;
Leukemia; 2021 Aug; 35(8):2358-2370. PubMed ID: 33526859
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
35. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A; Oñate G; Diaz-Beyá M; Guijarro F; Garrido A; Vives S; Tormo M; Arnan M; Salamero O; Sampol A; Coll R; Vall-Llovera F; Oliver-Caldés A; López-Guerra M; Pratcorona M; Zamora L; Villamon E; Roué G; Blanco A; Nomdedeu JF; Colomer D; Brunet S; Sierra J; Esteve J;
Br J Haematol; 2020 Oct; 191(1):52-61. PubMed ID: 32510599
[TBL] [Abstract][Full Text] [Related]
36. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
[TBL] [Abstract][Full Text] [Related]
37. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Lambert J; Lambert J; Nibourel O; Pautas C; Hayette S; Cayuela JM; Terré C; Rousselot P; Dombret H; Chevret S; Preudhomme C; Castaigne S; Renneville A
Oncotarget; 2014 Aug; 5(15):6280-8. PubMed ID: 25026287
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
40. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]